GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Open accessThe DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.
Abstract
Tirzepatide (LY3298176), a dual GIP and GLP-1 receptor (GLP-1R) agonist, delivered superior glycemic control and weight loss compared with GLP-1R agonism in patients with type 2 diabetes. However, the mechanism by which tirzepatide improves efficacy and how GIP receptor (GIPR) agonism contributes is not fully understood. Here, we show that tirzepatide is an effective insulin sensitizer, improving insulin sensitivity in obese mice to a greater extent than GLP-1R agonism. To determine whether GIPR agonism contributes, we compared the effect of tirzepatide in obese WT and Glp-1r-null mice. In the absence of GLP-1R-induced weight loss, tirzepatide improved insulin sensitivity by enhancing glucose disposal in white adipose tissue (WAT). In support of this, a long-acting GIPR agonist (LAGIPRA) was found to enhance insulin sensitivity by augmenting glucose disposal in WAT. Interestingly, the effect of tirzepatide and LAGIPRA on insulin sensitivity was associated with reduced branched-chain amino acids (BCAAs) and ketoacids in the circulation. Insulin sensitization was associated with upregulation of genes associated with the catabolism of glucose, lipid, and BCAAs in brown adipose tissue. Together, our studies show that tirzepatide improved insulin sensitivity in a weight-dependent and -independent manner. These results highlight how GIPR agonism contributes to the therapeutic profile of dual-receptor agonism, offering mechanistic insights into the clinical efficacy of tirzepatide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, binding to the GLP-1 receptor also seems significant in tirzepatide’s cell surface receptor mechanism, as tirzepatide had no effect on body weight, food intake, fasting insulin levels, skeletal muscle, subcutaneous adipose tissue endogenous glucose production, or insulin-stimulated glucose uptake in GLP-1 receptor non-expressing knockout mice [93].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In preclinical studies, tirzepatide improved insulin sensitivity in GLP-1 receptor null mice, thus demonstrating the important role of GIP receptor agonism in insulin sensitization [9] in addition to contributions of both GLP-1 and GIP receptor agonism to glucose-dependent insulin secretion [10].”
From Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1). (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postprandial excursions of insulin drive glucose dis posal through actions in muscle and adipose tissue, along with effects of postprandial excursions in GIP, to enhance insulin sensitivity and augment glucose disposal in adipose tissue (2-5).”
From Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In GlP-1 R-null mice, tirzepatide improved insulin sensitivity by enhancing glucose disposal in white adipose tissue in the absence of GLP-1 RA-induced weight loss.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [169]
The cited source says what the claim attributes to it.
In the citing paper
“Murine studies indicate that GIP-dependent insulin sensitization of adipose tissue may be another major GIP action [122].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [122]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 17×
“Thus, while it is likely to make a smaller contribution in humans (compared with mice), our data suggest that BAT may aid weight-dependent mechanisms in the lowering of circulating lipids and BCAAs, enhancing the improvement of insulin sensitivity by tirzepatide in patients with T2DM (44, 52).”
BackgroundInfluentialIdentification and Importance of Brown Adipose Tissue in Adult Humans
Cypess, A. M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldfine, A. B., Kuo, F. C., Palmer, E. L., Tseng, Y.-H., Doria, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810780 · Cited by 4,399
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Unexpected evidence for active brown adipose tissue in adult humans
Nedergaard, J., Bengtsson, T., & Cannon, B. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00691.2006 · Cited by 1,824 · cited 1×
“Therefore, while BAT has classically been considered to have a limited effect on human metabolism (72, 73), studies show that adult humans have functional BAT (74), which when activated, is capable of positively affecting systemic metabolism (43, 75, 76).”
BackgroundBrown adipose tissue activity controls triglyceride clearance
Bartelt, A., Bruns, O. T., Reimer, R., Hohenberg, H., Ittrich, H., Peldschus, K., Kaul, M. G., Tromsdorf, U. I., Weller, H., Waurisch, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2297 · Cited by 1,608
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
DeFronzo, R. A., Gunnarsson, R., Björkman, O., Olsson, M., & Wahren, J. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111938 · Cited by 1,167 · cited 1×
“Thus, although the specific contribution of WAT to total postprandial glucose clearance is not comparable to that of skeletal muscle (64, 65), the cumulative findings indicate that treatment with tirzepatide results in weight-independent insulin sensitivity in obese IR mice and that engagement of the GIPR accounts for…”
ResultInterplay between lipids and branched-chain amino acids in development of insulin resistance
Newgard, C. B. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.01.024 · Cited by 1,080 · cited 1×
“Although the cause of obesity-associated IR is intensely debated (4, 66, 67), recently, a strong association between elevated BCAAs/BCKAs, obesity, systemic IR, and T2DM has consistently been reported (66, 68).”
BackgroundActivation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist
Cypess, A. M., Weiner, L. S., Roberts-Toler, C., Elía, E. F., Kessler, S. H., Kahn, P. A., English, J., Chatman, K., Trauger, S. A., Doria, A., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2014.12.009 · Cited by 1,027
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Originally, the discovery that Gipr–/– mice are protected from obesity (54), in addition to studies showing that GIP enhances lipid storage in WAT (55, 56), led to the idea that GIP was obesogenic and consequently prompted several approaches to block GIP action (57).”
BackgroundIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 5×
“In addition, as GIP is the primary incretin in humans (17, 61), blockade of GIP action may be detrimental to glycemic control, while chronic GIPR agonism either has no effect on body weight or drives weight loss and improves insulin action in mice (23, 24, 28, 29, 62, 63).”
BackgroundResultInfluentialSelf-citationSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837
Measurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 18×
“Thus, while it is likely to make a smaller contribution in humans (compared with mice), our data suggest that BAT may aid weight-dependent mechanisms in the lowering of circulating lipids and BCAAs, enhancing the improvement of insulin sensitivity by tirzepatide in patients with T2DM (44, 52).”
BackgroundInfluentialSelf-citationAdipose tissue as a buffer for daily lipid flux
Frayn, K. (2002) · Diabetologia · doi:10.1007/s00125-002-0873-y · Cited by 752
Brown Adipose Tissue Improves Whole-Body Glucose Homeostasis and Insulin Sensitivity in Humans
Chondronikola, M., Volpi, E., Børsheim, E., Porter, C., Annamalai, P., Enerbäck, S., Lidell, M. E., Saraf, M. K., Labbe, S. M., Hurren, N. M., et al. (2014) · Diabetes · doi:10.2337/db14-0746 · Cited by 746
Brown adipose tissue is associated with cardiometabolic health
Becher, T., Palanisamy, S., Kramer, D. J., Eljalby, M., Marx, S. J., Wibmer, A. G., Butler, S. D., Jiang, C. S., Vaughan, R., Schöder, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-1126-7 · Cited by 743
The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis.
Crewe, C., An, Y. A., & Scherer, P. E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88883 · Cited by 732 · cited 17×
“Thus, while it is likely to make a smaller contribution in humans (compared with mice), our data suggest that BAT may aid weight-dependent mechanisms in the lowering of circulating lipids and BCAAs, enhancing the improvement of insulin sensitivity by tirzepatide in patients with T2DM (44, 52).”
BackgroundInfluentialUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 2×
“Consistent with data from other reports (23, 28, 29, 62), neither LAGIPRA nor tirzepatide (in GLP1R–KO animals) reduced body weight, supporting the hypothesis that GLP-1R agonism is required to unlock the synergistic action GIPR agonism on weight loss (18).”
BackgroundResultNonshivering thermogenesis and its adequate measurement in metabolic studies
Cannon, B., & Nedergaard, J. (2011) · Journal of Experimental Biology · doi:10.1242/jeb.050989 · Cited by 677 · cited 1×
“Thus, to maximize weight gain, circumvent protection from obesity, and ensure a state of IR, we exposed Glp-1r–/– animals to a 60% HFD and minimized thermal stress by housing animals in a thermal neutral (27°C) environment (38).”
BackgroundThe Origins and Drivers of Insulin Resistance
Johnson, A. M. F., & Olefsky, J. M. (2013) · Cell · doi:10.1016/j.cell.2013.01.041 · Cited by 643
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 1×
“The most advanced multireceptor agonist is tirzepatide (LY3298176), an imbalanced and biased GIP and GLP-1R agonist (28, 30).”
BackgroundSelf-citationBCAA catabolism in brown fat controls energy homeostasis through SLC25A44
Yoneshiro, T., Wang, Q., Tajima, K., Matsushita, M., Maki, H., Igarashi, K., Dai, Z., White, P. J., McGarrah, R. W., Ilkayeva, O. R., et al. (2019) · Nature · doi:10.1038/s41586-019-1503-x · Cited by 534
She, P., Van Horn, C., Reid, T., Hutson, S. M., Cooney, R. N., & Lynch, C. J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00134.2007 · Cited by 502
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Self-citationDose-response curves for in vivo insulin sensitivity in individual tissues in rats
Kraegen, E. W., James, D. E., Jenkins, A. B., & Chisholm, D. J. (1985) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1985.248.3.e353 · Cited by 408
Adipose Tissue Branched Chain Amino Acid (BCAA) Metabolism Modulates Circulating BCAA Levels
Herman, M. A., She, P., Peroni, O. D., Lynch, C. J., & Kahn, B. B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.075184 · Cited by 397
Thiazolidinediones: the forgotten diabetes medications
Lebovitz, H. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1270-y · Cited by 388
Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity
O’Mara, A. E., Johnson, J. W., Linderman, J. D., Brychta, R. J., McGehee, S., Fletcher, L. A., Fink, Y. A., Kapuria, D., Cassimatis, T. M., Kelsey, N., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131126 · Cited by 368
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa863 · Cited by 345 · cited 2×
“In support of this hypothesis, HOMA-IR analysis has suggested that a significant proportion of tirzepatide-induced insulin sensitization occurs in the absence of weight loss in subjects with T2DM (52).”
BackgroundMethodBrown Adipose Tissue Activation Is Linked to Distinct Systemic Effects on Lipid Metabolism in Humans
Chondronikola, M., Volpi, E., Børsheim, E., Porter, C., Saraf, M. K., Annamalai, P., Yfanti, C., Chao, T., Wong, D., Shinoda, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.04.029 · Cited by 326
Lackey, D. E., Lynch, C. J., Olson, K. C., Mostaedi, R., Ali, M., Smith, W. H., Karpe, F., Humphreys, S., Bedinger, D. H., Dunn, T. N., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00630.2012 · Cited by 319
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12384 · Cited by 314 · cited 1×
“One of the most effective therapies for the treatment of T2DM is weight loss (48, 49).”
BackgroundIt's Not How Fat You Are, It's What You Do with It That Counts
Virtue, S., & Vidal-Puig, A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060237 · Cited by 312
Branched-chain amino acids in disease
White, P. J., & Newgard, C. B. (2019) · Science · doi:10.1126/science.aav0558 · Cited by 302
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Hedbacker, K., Birsoy, K., Wysocki, R. W., Asilmaz, E., Ahima, R. S., Farooqi, I. S., & Friedman, J. M. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.007 · Cited by 280
GIF biology and fat metabolism
Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266
Adiponectin, driver or passenger on the road to insulin sensitivity?
Ye, R., & Scherer, P. E. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.04.001 · Cited by 251
Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237 · cited 2×
“A key finding of the current study is that tirzepatide ameliorated peripheral IR in a model of DIO.”
BackgroundOptimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s141235 · Cited by 223 · cited 1×
“However, although the GLP-1RA class has improved the standard of care, many patients still do not reach their glycemic targets (10), and thus, there remains a need to identify agents capable of complementing the actions of GLP-1RAs.”
BackgroundPioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118825376 · Cited by 223 · cited 1×
“To date, caloric restriction–mediated weight loss, bariatric surgery, or pharmacotherapy with thiazolidinediones (TZDs, small-molecule agonists of the nuclear hormone receptor PPARγ) are the only effective approaches that specifically treat IR for improving glucose control (5).”
BackgroundGastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes
Eckel, R. H., Fujimoto, W. Y., & Brunzell, J. D. (1979) · Diabetes · doi:10.2337/diab.28.12.1141 · Cited by 219
Adipose Tissue Function and Expandability as Determinants of Lipotoxicity and the Metabolic Syndrome
Carobbio, S., Pellegrinelli, V., & Vidal-Puig, A. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-48382-5_7 · Cited by 194
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
Kim, S.-J., Nian, C., Karunakaran, S., Clee, S. M., Isales, C. M., & McIntosh, C. H. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040156 · Cited by 182 · cited 5×
“Overexpression of GIP or administration of long-acting GIPR agonists (LAGIPRAs) enhances whole-body insulin sensitivity in models of obesity-induced IR (23, 24).”
BackgroundResultInfluentialReappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Cannon, B., & Nedergaard, J. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.177 · Cited by 176
Metabolic characteristics of human adipose tissue in vivo
Frayn, K. N., Coppack, S. W., Humphreys, S. M., & Whyte, P. L. (1989) · Clinical Science · doi:10.1042/cs0760509 · Cited by 170
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s008 · Cited by 148
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133 · cited 1×
“In addition, as GIP is the primary incretin in humans (17, 61), blockade of GIP action may be detrimental to glycemic control, while chronic GIPR agonism either has no effect on body weight or drives weight loss and improves insulin action in mice (23, 24, 28, 29, 62, 63).”
BackgroundIwen, K. A., Backhaus, J., Cassens, M., Waltl, M., Hedesan, O. C., Merkel, M., Heeren, J., Sina, C., Rademacher, L., Windjäger, A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01250 · Cited by 128
Delahanty, L. M., Pan, Q., Jablonski, K. A., Aroda, V. R., Watson, K. E., Bray, G. A., Kahn, S. E., Florez, J. C., Perreault, L., Franks, P. W., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0018 · Cited by 125 · cited 1×
“One of the most effective approaches to achieving clinically meaningful improvements in glycemic control is weight loss (35).”
BackgroundChen, K. Y., Brychta, R. J., Abdul Sater, Z., Cassimatis, T. M., Cero, C., Fletcher, L. A., Israni, N. S., Johnson, J. W., Lea, H. J., Linderman, J. D., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.007363 · Cited by 111
Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
Kaneko, K., Fu, Y., Lin, H.-Y., Cordonier, E. L., Mo, Q., Gao, Y., Yao, T., Naylor, J., Howard, V., Saito, K., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126107 · Cited by 106 · cited 2×
“A key finding of the current study is that tirzepatide ameliorated peripheral IR in a model of DIO.”
BackgroundMohammad, S., Patel, R. T., Bruno, J., Panhwar, M. S., Wen, J., & McGraw, T. E. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00256-14 · Cited by 104
Scrocchi, L. A., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.7.6092 · Cited by 95
Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
Beck, B., & Max, J. (1983) · Regulatory Peptides · doi:10.1016/0167-0115(83)90276-8 · Cited by 91
Varol, C., Zvibel, I., Spektor, L., Mantelmacher, F. D., Vugman, M., Thurm, T., Khatib, M., Elmaliah, E., Halpern, Z., & Fishman, S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401149 · Cited by 89
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85 · cited 1×
“Originally, the discovery that Gipr–/– mice are protected from obesity (54), in addition to studies showing that GIP enhances lipid storage in WAT (55, 56), led to the idea that GIP was obesogenic and consequently prompted several approaches to block GIP action (57).”
BackgroundLeveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 83
Self-citationPhysiological roles of the GIP receptor in murine brown adipose tissue
Beaudry, J. L., Kaur, K. D., Varin, E. M., Baggio, L. L., Cao, X., Mulvihill, E. E., Bates, H. E., Campbell, J. E., & Drucker, D. J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.006 · Cited by 76
GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women
Rudovich, N. N., Kaiser, S., Engeli, S., Osterhoff, M. A., Gögebakan, Ö., Blüher, M., & Pfeiffer, A. F. H. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.02.006 · Cited by 74
Fonseca, V. A., Capehorn, M., Garg, S. K., Gimeno, E. J., Hansen, O. H., Holst, A. G., Nayak, G., & Seufert, J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02685 · Cited by 71
Pharmacological antagonism of the incretin system protects against diet-induced obesity
Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.018 · Cited by 67
GIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family
Nauck, M. A., & Meier, J. J. (2019) · Diabetes · doi:10.2337/dbi19-0005 · Cited by 65
Mohammad, S., Ramos, L. S., Buck, J., Levin, L. R., Rubino, F., & McGraw, T. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.289009 · Cited by 59
Beavers, D. P., Beavers, K. M., Lyles, M. F., & Nicklas, B. J. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls236 · Cited by 56
Mechanisms to Elevate Endogenous GLP-1 Beyond Injectable GLP-1 Analogs and Metabolic Surgery
Briere, D. A., Bueno, A. B., Gunn, E. J., Michael, M. D., & Sloop, K. W. (2018) · Diabetes · doi:10.2337/db17-0607 · Cited by 50
Self-citationSloop, K. W., Briere, D. A., Emmerson, P. J., & Willard, F. S. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00009 · Cited by 31 · cited 1×
“Discussion Multireceptor pharmacology is at the forefront of next-generation therapies for the treatment of metabolic diseases (27, 45).”
BackgroundSelf-citationBeavers, K. M., Case, L. D., Blackwell, C. S., Katula, J. A., Goff, D. C., & Vitolins, M. Z. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2014.09.003 · Cited by 19
THOMAS, M. K., NIKOOIENEJAD, A., BRAY, R., CUI, X., WILSON, J. M., DUFFIN, K. L., MILICEVIC, Z., HAUPT, A., & ROBINS, D. A. (2019) · Diabetes · doi:10.2337/db19-980-p · Cited by 8
Cited by
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416394 · Cited by 634
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Metadata
- Authors
- Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., Furber, E. P. S. C., Ruan, X., O’Farrell, L. S., Long, A. M., Dogra, M., Willency, J. A., Lin, Y., Ding, L., Cheng, C. C., Cabrera, O., Briere, D. A., Alsina-Fernandez, J., Gimeno, R. E., Moyers, J. S., Coskun, T., Coghlan, M. P., Sloop, K. W., & Roell, W. C.
- Affiliations
- Eli Lilly (United States) (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2021-06-15
- Volume
- 131
- Issue
- 12
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC8203452
- OpenAlex
- W3161292733
- Cited by
- 256
- References
- 82
- Citations by year
- 2026: 58 · 2025: 66 · 2024: 54 · 2023: 34 · 2022: 34 · 2021: 10
- FWCI
- 24.64
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- tirzepatide, GLP-1 receptor agonism, insulin sensitization, obesity, type 2 diabetes, glucose disposal, white adipose tissue, brown adipose tissue, branched-chain amino acids, keto acids
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Amino Acids, Branched-Chain, Animals, Body Weight, Gastric Inhibitory Polypeptide, Insulin Resistance, Obesity, Mice, Knockout, Mice, Adipose Tissue, White
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.